* Qiagen NV, of Venlo, the Netherlands, sold its synthetic DNA business to a management team previously employed at the company for $24.3 million in cash and in the form of a promissory note. Qiagen will retain a 16 percent stake in the new company, called Operon Biotechnologies Inc. It retains all rights and activities in its siRNA business, including ownership of its TOM-amidite chemistry, and will receive preferred access to Operon's synthetic nucleic …
No comments:
Post a Comment